Pharma channel feed

FDA push­es eczema de­ci­sion for Eli Lil­ly's Olu­mi­ant, Pfiz­er's abroc­i­tinib back 3 months — rais­ing more ques­tions for the JAK class

5 years ago
FDA+

As­traZeneca’s big ADC part­ner pledges to pour $13.6B in­to can­cer R&D over next 5 years — and En­her­tu looms large

5 years ago

De­spite remde­sivir ap­proval and 2 big buy­outs, Gilead CEO Dan O'­Day sees pay fall 35% from 2019

5 years ago
People

As Covid-19 vac­cine was be­ing de­vel­oped, Mod­er­na shelled out more than $1M for top ex­ec­u­tives' se­cu­ri­ty

5 years ago
People

Eu­ro­pean Com­mis­sion preps for ma­jor over­haul of phar­ma leg­is­la­tion

5 years ago
FDA+

MHRA kicks off new ac­cel­er­at­ed drug ap­proval path­way with ‘in­no­va­tion pass­ports’

5 years ago
FDA+

2,400 peo­ple re­main with­out rare dis­ease drug as Take­da man­u­fac­tur­ing woes con­tin­ue

5 years ago
Manufacturing

Why the Biden ad­min­is­tra­tion might not want to be con­tent with just an act­ing FDA com­mis­sion­er

5 years ago
FDA+

Glax­o­SmithK­line of­floads roy­al­ty rights for 2 can­cer drugs in $342M wind­fall it will use to fi­nance con­sumer spin­off

5 years ago

Bris­tol My­ers faces $1B+ tax fight af­ter ac­ci­den­tal dis­clo­sure re­veals al­leged off­shore patents scheme — re­port

5 years ago
FDA+

Move over, Boston and San Fran­cis­co? Seat­tle tops list of fastest grow­ing biotech hubs for job op­por­tu­ni­ties — re­port

5 years ago

How Biden’s in­fra­struc­ture plan will go af­ter bio­phar­ma com­pa­nies be­yond drug pric­ing

5 years ago

House Dems seek to over­turn Trump-era rule that could gut FDA’s reg­u­la­tions

5 years ago
FDA+

HHS reg­u­la­to­ry agen­da for 2021 is light on new pro­posed and fi­nal FDA rules

5 years ago
FDA+

Af­ter dis­miss­ing CFO over 'i­nap­pro­pri­ate mes­sages,' Eli Lil­ly faces new ac­cu­sa­tions of sex­u­al dis­crim­i­na­tion and ha­rass­ment

5 years ago

The IBD mar­ket is set to soar to $32B. Ab­b­Vie could be the big win­ner, but there's meat left on the bone — top an­a­lyst

5 years ago

FDA busts Mer­ck­'s Keytru­da in triple-neg­a­tive breast can­cer with a CRL — not un­ex­pect­ed giv­en its dis­as­trous ad­comm

5 years ago
FDA+

No­var­tis and Genen­tech push for clar­i­ty from FDA on how dis­ease pro­gres­sion mod­els can be used for reg­u­la­to­ry de­ci­sions

5 years ago
FDA+

FDA puts its foot down on Mak­e­na: New meta-analy­sis does not change call to pull the drug

5 years ago
FDA+

French court finds Servi­er guilty of manslaugh­ter in di­et pill tri­al, fines phar­ma mil­lions

5 years ago

House Dems call on the FTC to in­ves­ti­gate po­ten­tial col­lu­sion among top three in­sulin man­u­fac­tur­ers

5 years ago
FDA+

No­var­tis push­es back on chair­man's 'i­nac­cu­rate and in­con­sis­ten­t' com­ments un­der­min­ing bribery set­tle­ment

5 years ago

No­var­tis walks away from 3rd Zol­gens­ma plant just a year af­ter leas­ing it as it piv­ots re­sources to next-gen pipeline

5 years ago
Manufacturing

FDA ex­pert pan­el lines up 19-to-1 against Pfiz­er’s os­teoarthri­tis drug tanezum­ab

5 years ago
FDA+
First page Previous page 243244245246247248249 Next page Last page
A service from the Financial Times